Background The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. We estimated the cost-effectiveness of introducing either PCV10 or the13-valent vaccine (PCV13) from a societal perspective and explored the incremental impact of including indirect vaccine effects. Methods The costs and effects of pneumococcal vaccination among infants born in Kenya in 2010 were assessed using a decision analytic model comparing PCV10 or PCV13, in turn, with no vaccination. Direct vaccine effects were estimated as a reduction in the incidence of pneumococcal meningitis, sepsis, bacteraemic pneumonia and non-bacteraemic pneumonia. Pneumococcal disease incidence was extrapolated from a population-based hospital surve...
Summary: Background: In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Ma...
BACKGROUND: Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of a...
BACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commit...
The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. W...
The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. W...
<div><p>Background</p><p>The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10)...
Background The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction ...
Summary: Background: Introduction of pneumococcal conjugate vaccines (PCVs) has substantially reduc...
Background Pneumococcal disease, caused by Streptococcus pneumoniae (S. pneumoniae), leads to a gr...
*<p>All costs, pneumococcal episodes and deaths are discounted at an annual rate of 3%.</p
Objective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vac...
SummaryBackgroundThe effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countries ...
OBJECTIVE: To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate va...
Abstract Objectives To evaluate the cost effectiveness of the use of nine-valent pneumococcal polys...
Abstract Objectives To evaluate the cost effectiveness of the use of nine-valent pneumococcal polys...
Summary: Background: In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Ma...
BACKGROUND: Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of a...
BACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commit...
The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. W...
The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. W...
<div><p>Background</p><p>The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10)...
Background The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction ...
Summary: Background: Introduction of pneumococcal conjugate vaccines (PCVs) has substantially reduc...
Background Pneumococcal disease, caused by Streptococcus pneumoniae (S. pneumoniae), leads to a gr...
*<p>All costs, pneumococcal episodes and deaths are discounted at an annual rate of 3%.</p
Objective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vac...
SummaryBackgroundThe effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countries ...
OBJECTIVE: To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate va...
Abstract Objectives To evaluate the cost effectiveness of the use of nine-valent pneumococcal polys...
Abstract Objectives To evaluate the cost effectiveness of the use of nine-valent pneumococcal polys...
Summary: Background: In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Ma...
BACKGROUND: Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of a...
BACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commit...